Wednesday, February 18, 2026 2/18/2026

Role of Intestinal Proteostasis mediator HSP90 in alcoholic liver disease.

Award Number: R21AA029260
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Role of Intestinal Proteostasis mediator HSP90 in alcoholic liver disease. - ABSTRACT Chronic alcohol alters the enteric microbiome (dysbiosis), induces inflammation, impairs the gut barrier function resulting in a “leaky” gut, passage of microbial products into portal circulation and eventually liver inflammation. Current therapies targeting the microbiome or host pathways to restore barrier function have utilized antibiotics, probiotics, synbiotics, fecal microbiome transplant (FMT), bacteriophage therapy, FXR agonists and nutrient- based treatments. The major goal of this proposal is to investigate the pathogenic role of proteostasis mediator, HSP90 in the gut by intestinal targeting in vivo using specific pharmacological inhibitors to evaluate its effect on alcohol mediated host intestinal inflammation, barrier function and dysbiosis. Two predominant forms of mammalian stress inducible HSP90 paralogs are cytoplasmic (CYT) HSP90AA1 and HSP90B1/GP96 in the endoplasmic reticulum (ER). The chaperone function of HSP90 and GP96 is crucial in fine tuning immune cell activation and inflammatory responses. The precise role of proteostasis chaperones such as HSP90 in chronic alcohol mediated intestinal dysfunction is not yet investigated. We reported that targeting HSP90 using specific pharmacological inhibitor 17-DMAG, reduced gut derived circulating endotoxin in ALD. Myeloid specific HSP90B1/GP96 deficient mice also exhibit reduced circulating endotoxin in ALD. Further our preliminary data show induction of HSP90AA1 and HSP90B1/GP96 mRNA in intestine of chronic alcohol exposed mice. In addition, 17-DMAG is bioavailable in the intestine and inhibits inflammatory cytokine, TNFα in the jejunum and ileum. We hypothesize that chronic alcohol induces HSP90 in host intestine contributing to inflammation and compromising gut barrier function in ALD. In addition, since therapeutic targeting of gut inflammation can restore protective microbiota, as well as considering the antibiotic and antimycotic properties of 17-DMAG, it is likely that 17-DMAG treatment favors protective gut microbiota, facilitated by reduced host intestinal inflammation. Collectively, here we will explore the role of HSP90 in alcohol mediated gut inflammation and barrier function and also assess whether pharmacological targeting of host HSP90 impacts gut microbiota. The Specific Aims are: 1) To delineate the role of HSP90 isoforms on alcohol induced gut inflammation by- Evaluating expression of HSP90 isoforms, intestinal targeting of HSP90 using 17-DMAG encapsulated nanoparticles to study inflammatory responses in small intestine and immune cells in lamina propria and assessing whether myeloid specific HSP90B1/GP96 deficiency affects inflammatory responses in the gut. 2) To assess the functional relevance of HSP90 on alcohol mediated intestinal barrier integrity and dysbiosis by - Evaluating permeability and epithelial tight junction proteins during HSP90 and myeloid GP96 inhibition. B) Assessing the effect of intestine targeted nano-DMAG and myeloid GP96 deficiency on microbiota. Successful completion of the proposed studies will uncover the role of proteostasis chaperones in the gut and guide future studies to identify proteostasis pathways in alcohol mediated gut injury.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$48,021 )
2025	2022	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	000	2	5/19/2025	NON-COMPETING CONTINUATION	$0
2025	2022	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	001	2	5/30/2025	NON-COMPETING CONTINUATION	-$48,021
														Subtotal = -$48,021

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	55 LAKE AVE N	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	000	2	2/14/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $198,906 )
2022	2022	UNIVERSITY OF MASSACHUSETTS	55 LAKE AVE NORTH	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	001	2	8/8/2022	NON-COMPETING CONTINUATION	$198,906
2022	2021	UNIVERSITY OF MASSACHUSETTS	55 LAKE AVE NORTH	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	000	1	11/9/2021	NEW	$0
														Subtotal = $198,906

Issue Date FY: 2021 ( Subtotal = $255,064 )
2021	2021	UNIVERSITY OF MASSACHUSETTS	55 LAKE AVE NORTH	WORCESTER	MA	01655	WORCESTER	USA	Alcohol Research Programs	000	1	9/23/2021	NEW	$255,064
														Subtotal = $255,064

Grand Total All Awards = $405,949

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of Intestinal Proteostasis mediator HSP90 in alcoholic liver disease.

Award Number: R21AA029260

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer